摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2-hydroxyphenyl)-2-(4-methoxyphenyl)propan-1-one | 1396756-73-2

中文名称
——
中文别名
——
英文名称
1-(2-hydroxyphenyl)-2-(4-methoxyphenyl)propan-1-one
英文别名
——
1-(2-hydroxyphenyl)-2-(4-methoxyphenyl)propan-1-one化学式
CAS
1396756-73-2
化学式
C16H16O3
mdl
——
分子量
256.301
InChiKey
WLMYYCQRBTVVCI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.39
  • 重原子数:
    19.0
  • 可旋转键数:
    4.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    46.53
  • 氢给体数:
    1.0
  • 氢受体数:
    3.0

反应信息

  • 作为产物:
    描述:
    3-bromo-4-(4-methoxyphenyl)-6,6-dimethyl-5,6-dihydro-4H-1,2-oxazine N-oxide 在 5%-palladium/activated carbon 、 氢气 、 cesium fluoride 作用下, 以 甲醇乙腈 为溶剂, 反应 5.0h, 生成 1-(2-hydroxyphenyl)-2-(4-methoxyphenyl)propan-1-one
    参考文献:
    名称:
    3-卤代-5,6-二氢-4H-1,2-恶嗪 N-氧化物作为与芳烃进行 [3 + 2]-环加成反应中不饱和腈氧化物的合成等价物:取代的 3-乙烯基-1,2- 的合成苯并异恶唑类
    摘要:
    研究了3-卤代-5,6-二氢-4H -1,2-恶嗪N-氧化物与芳烃的反应。芳烃由邻甲硅烷基芳基三氟甲磺酸酯生成,并与N-氧化物进行连续的[3 + 2]-环加成/[4 + 2]-环化还原,以高产率产生取代的3-乙烯基-苯并异恶唑。在所提出的序列中,1,2-恶嗪N-氧化物充当很少使用的不饱和腈氧化物的替代物。展示了广泛的底物范围。确定了芳基的取代模式对反应结果的影响。在大取代基存在下,选择性地形成多环4,4a-二氢-3H-苯并呋喃并[3,2- c ][1,2]恶嗪。提出了观察到的反应途径的机理方案。产品的合成实用性通过其后续修饰得到了证明。
    DOI:
    10.1039/d4ob00391h
点击查看最新优质反应信息

文献信息

  • Rhodium-Phosphoramidite Catalyzed Alkene Hydroacylation: Mechanism and Octaketide Natural Product Synthesis
    作者:Max von Delius、Christine M. Le、Vy M. Dong
    DOI:10.1021/ja305593y
    日期:2012.9.12
    heterogeneous base are key for high catalytic activity and linear regioselectivity. This protocol was applied in the atom- and step-economical synthesis of eight biologically active octaketide natural products, including anticancer drug candidate cytosporone B. Mechanistic studies provide insight on parameters affecting decarbonylation, a side reaction that limits the turnover number for catalytic hydroacylation
    我们描述了一种方法,该方法允许水杨醛衍生物以低至 2 mol% 的催化剂负载量与各种未活化的烯烃偶联。手性亚磷酰胺配体和多相碱的精确化学计量是高催化活性和线性区域选择性的关键。该协议应用于八种生物活性八酮天然产物的原子和步骤经济合成,包括抗癌药物候选细胞孢菌素 B。 机理研究提供了对影响脱羰的参数的见解,这是一种限制催化加氢酰化转换数的副反应。氘标记研究表明,支化氢化物插入是完全可逆的,而线性氢化物插入在很大程度上是不可逆的并且限制了转换。我们建议配体 (R(a),R, R)-SIPHOS-PE 通过降低线性选择性途径中还原消除的障碍,有效抑制脱羰,并有助于限制转换的插入。这些因素共同实现了高反应性和区域选择性。
  • 3-Halo-5,6-dihydro-4<i>H</i>-1,2-oxazine <i>N</i>-oxides as synthetic equivalents of unsaturated nitrile oxides in the [3 + 2]-cycloaddition with arynes: synthesis of substituted 3-vinyl-1,2-benzisoxazoles
    作者:Alexander A. Lukoyanov、Svetlana A. Aksenova、Andrey A. Tabolin、Alexey Yu. Sukhorukov
    DOI:10.1039/d4ob00391h
    日期:——
    The reaction of 3-halo-5,6-dihydro-4H-1,2-oxazine N-oxides with arynes was studied. Arynes were generated from o-silylaryl triflates and underwent consecutive [3 + 2]-cycloaddition/[4 + 2]-cycloreversion with N-oxides leading to substituted 3-vinyl-benzisoxazoles in high yields. In the presented sequence, 1,2-oxazine N-oxides act as surrogates of rarely employed unsaturated nitrile oxides. A broad
    研究了3-卤代-5,6-二氢-4H -1,2-恶嗪N-氧化物与芳烃的反应。芳烃由邻甲硅烷基芳基三氟甲磺酸酯生成,并与N-氧化物进行连续的[3 + 2]-环加成/[4 + 2]-环化还原,以高产率产生取代的3-乙烯基-苯并异恶唑。在所提出的序列中,1,2-恶嗪N-氧化物充当很少使用的不饱和腈氧化物的替代物。展示了广泛的底物范围。确定了芳基的取代模式对反应结果的影响。在大取代基存在下,选择性地形成多环4,4a-二氢-3H-苯并呋喃并[3,2- c ][1,2]恶嗪。提出了观察到的反应途径的机理方案。产品的合成实用性通过其后续修饰得到了证明。
查看更多

同类化合物

安哥拉紫檀素 2-羟基-3-苯基苯丙酮 1-(2,4-二羟基苯基-3,5-d2)-2-(4-羟基苯基-3,5-d2)丙烷-1-酮-2-d1 1-(2,4-二羟基苯基)-2-(4-羟基苯基)丙-1-酮 1-(1-羟基萘-2-基)-2-甲基-2-苯基丙烷-1-酮 1-(2-hydroxy-5-methylphenyl)-3-(naphthalen-1-yl)-2-phenylpropan-1-one 2,4,5,4'-tetramethoxy-α-methyldesoxybenzoin 1-[2-(1-hydroxynaphthyl)]-2-phenyl-1-propanone 1-(4-(cyc lohexyloxy)-2-methoxyphenyl)-2-(3,4-dimethoxyphenyl)propan-1-one 2-(3,4-dimethoxyphenyl)-1-(4-hydroxy-2-methoxyphenyl)propan-1-one 1-(2-Hydroxy-4-methoxyphenyl)-2-(4-hydroxyphenyl)propan-1-one 1-(2-methoxyphenyl)-2-phenylpropan-1-one 2-(2-fluorophenyl)-1-(2-methoxy-4-(piperidin-1-yl)phenyl)propan-1-one (-)-angolensin (-)-angolensin-4-methyl ether 1-(2-methoxyphenyl)-2-phenyl-2-(trimethylsilyloxy)propan-1-one 1-(2,5-dimethoxy-4-methylphenyl)-2-phenylpropan-1-one (+/-)-1-<2,5-Dimethyl-phenyl>-2-phenyl-propan-1-on 1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)-[1,2,3-(13)C3]propan-1-one 1,2-bis(2-hydroxybenzoyl)-1-propanone 2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-methylpropan-1-one (+/-)-2-<2,4-Bis(methoxymethoxy)phenyl>-1-<2-hydroxy-4-(methoxymethoxy)phenyl>propan-1-on 1-(2-hydroxyphenyl)-2-(4-methoxyphenyl)propan-1-one 1-(2,4-dimethoxyphenyl)-2-(4-methoxyphenyl)-2-methylpropan-1-one 1-(2-hydroxy-4-methoxyphenyl)-2-(4-methoxyphenyl)-2-methylpropan-1-one 1-(2-hydroxy-4-methoxyphenyl)-2-phenylpropan-1-one 1-(2-hydroxyphenyl)-2-(2-hydroxy-4-methoxyphenyl)-1-propanone 2-hydroxy-3,4-dimethoxy-α-C-methoxydesoxybenzoin (R)-2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one 2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one 1-(2,5-dihydroxy-4-methoxyphenyl)-2-(4'-hydroxyphenyl)-1-propanone 1-(5-Bromo-2-hydroxyphenyl)-2-(2-nitrophenyl)propan-1-one 1-(2,5-dihydroxy-4-methoxyphenyl)-2-phenyl-1-propanone 1-(2,4-Dihydroxyphenyl)-2-phenylpropan-1-one 1-(2,3,4-trihydroxyphenyl)-2-phenyl-1-propanone (S)-2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one Ethyl 4-[1-[4-(dimethylamino)-2-hydroxyphenyl]-1-oxopropan-2-yl]benzoate 2-[[2-(2-Methyl-2-phenylpropanoyl)phenoxy]methoxy]propyl benzoate (2S)-1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)propan-1-one 1-[2,4-Bis(trimethylsiloxy)phenyl]-2-[(4-trimethylsiloxy)phenyl]propan-1-one 1-(2,4-dimethoxyphenyl)-2-(4-methoxyphenyl)propan-1-one (+/-)-Di-O-acetyl-angolensin 4'-hydroxy-2,4-dimethoxy-α-methyldeoxybenzoin 1-(2,3,4-dihydroxyphenyl)-2-(4'-hydroxyphenyl)-1-propanone 1-(2,4-Dihydroxyphenyl)-2-(3-hydroxy-4-methoxyphenyl)propan-1-one 2-(4-Methoxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one 1-(2,4-Dihydroxyphenyl)-2-(3,5-dimethoxyphenyl)propan-1-one 1-[4-[(1,6-dimethyl-4-propan-2-yl-3,4,4a,7,8,8a-hexahydro-2H-naphthalen-1-yl)oxy]-2-hydroxyphenyl]-2-(4-methoxyphenyl)propan-1-one 1-(2,4-Dihydroxy-5-methoxyphenyl)-2-(4-hydroxyphenyl)propan-1-one (+/-)-4-O-methylangolensin